Lance Miller to Treatment Outcome
This is a "connection" page, showing publications Lance Miller has written about Treatment Outcome.
Connection Strength
0.285
-
Miller LD, Coffman LG, Chou JW, Black MA, Bergh J, D'Agostino R, Torti SV, Torti FM. An iron regulatory gene signature predicts outcome in breast cancer. Cancer Res. 2011 Nov 01; 71(21):6728-37.
Score: 0.056
-
Broët P, Camilleri-Broët S, Zhang S, Alifano M, Bangarusamy D, Battistella M, Wu Y, Tuefferd M, Régnard JF, Lim E, Tan P, Miller LD. Prediction of clinical outcome in multiple lung cancer cohorts by integrative genomics: implications for chemotherapy selection. Cancer Res. 2009 Feb 01; 69(3):1055-62.
Score: 0.047
-
Broët P, Kuznetsov VA, Bergh J, Liu ET, Miller LD. Identifying gene expression changes in breast cancer that distinguish early and late relapse among uncured patients. Bioinformatics. 2006 Jun 15; 22(12):1477-85.
Score: 0.038
-
Jimenez H, Wang M, Zimmerman JW, Pennison MJ, Sharma S, Surratt T, Xu ZX, Brezovich I, Absher D, Myers RM, DeYoung B, Caudell DL, Chen D, Lo HW, Lin HK, Godwin DW, Olivier M, Ghanekar A, Chen K, Miller LD, Gong Y, Capstick M, D'Agostino RB, Munden R, Merle P, Barbault A, Blackstock AW, Bonkovsky HL, Yang GY, Jin G, Liu L, Zhang W, Watabe K, Blackman CF, Pasche BC. Tumour-specific amplitude-modulated radiofrequency electromagnetic fields induce differentiation of hepatocellular carcinoma via targeting Cav3.2?T-type voltage-gated calcium channels and Ca2+ influx. EBioMedicine. 2019 Jun; 44:209-224.
Score: 0.024
-
Pardee TS, Anderson RG, Pladna KM, Isom S, Ghiraldeli LP, Miller LD, Chou JW, Jin G, Zhang W, Ellis LR, Berenzon D, Howard DS, Hurd DD, Manuel M, Dralle S, Lyerly S, Powell BL. A Phase I Study of CPI-613 in Combination with High-Dose Cytarabine and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia. Clin Cancer Res. 2018 05 01; 24(9):2060-2073.
Score: 0.022
-
Manna S, Bostner J, Sun Y, Miller LD, Alayev A, Schwartz NS, Lager E, Fornander T, Nordenskjöld B, Yu JJ, Stål O, Holz MK. ERRa Is a Marker of Tamoxifen Response and Survival in Triple-Negative Breast Cancer. Clin Cancer Res. 2016 Mar 15; 22(6):1421-31.
Score: 0.019
-
Pardee TS, Lee K, Luddy J, Maturo C, Rodriguez R, Isom S, Miller LD, Stadelman KM, Levitan D, Hurd D, Ellis LR, Harrelson R, Manuel M, Dralle S, Lyerly S, Powell BL. A phase I study of the first-in-class antimitochondrial metabolism agent, CPI-613, in patients with advanced hematologic malignancies. Clin Cancer Res. 2014 Oct 15; 20(20):5255-64.
Score: 0.017
-
Stovall DB, Wan M, Miller LD, Cao P, Maglic D, Zhang Q, Stampfer MR, Liu W, Xu J, Sui G. The regulation of SOX7 and its tumor suppressive role in breast cancer. Am J Pathol. 2013 Nov; 183(5):1645-1653.
Score: 0.016
-
Landen CN, Goodman B, Katre AA, Steg AD, Nick AM, Stone RL, Miller LD, Mejia PV, Jennings NB, Gershenson DM, Bast RC, Coleman RL, Lopez-Berestein G, Sood AK. Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. . 2010 Dec; 9(12):3186-99.
Score: 0.013
-
Pinnix ZK, Miller LD, Wang W, D'Agostino R, Kute T, Willingham MC, Hatcher H, Tesfay L, Sui G, Di X, Torti SV, Torti FM. Ferroportin and iron regulation in breast cancer progression and prognosis. Sci Transl Med. 2010 Aug 04; 2(43):43ra56.
Score: 0.013
-
Lin CY, Ström A, Li Kong S, Kietz S, Thomsen JS, Tee JB, Vega VB, Miller LD, Smeds J, Bergh J, Gustafsson JA, Liu ET. Inhibitory effects of estrogen receptor beta on specific hormone-responsive gene expression and association with disease outcome in primary breast cancer. Breast Cancer Res. 2007; 9(2):R25.
Score: 0.010
-
Frasor J, Chang EC, Komm B, Lin CY, Vega VB, Liu ET, Miller LD, Smeds J, Bergh J, Katzenellenbogen BS. Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome. Cancer Res. 2006 Jul 15; 66(14):7334-40.
Score: 0.010